The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Earlier this week, Regeneron Pharmaceuticals announced its acquisition of 23andMe for $256 million, marking a strategic step in the industry-wide shift toward data-driven drug discovery. The move ...

In a landmark move within the biotech industry, Regeneron Pharmaceuticals has announced its acquisition of 23andMe for $256 million. This deal, emerging from 23andMe's bankruptcy proceedings ...

Is Regeneron a good stock to buy now in light of a potential 23andMe acquisition? Here's a quick look at what it's paying for to find out. 23andMe's market cap peaked at $5.8 billion a few months ...

On May 19, Regeneron agreed to acquire 23andMe for $256 million. The potential acquisition is still subject to bankruptcy court approval. At its peak, 23andMe's market value swelled to $5.8 billion.

23andMe's sale to Regeneron transfers genetic data for drug development, raising privacy issues and concerns over consumer control and benefits. Genetic information submitted by millions of ...